You are here

  • Home
  • Archive
  • Volume 71, Issue 12
  • Updated meta-analysis of non-melanoma skin cancer rates reported from prospective observational studies in patients treated with tumour necrosis factor inhibitors

Article Text

Article menu
Download PDFPDF
Electronic pages
Updated meta-analysis of non-melanoma skin cancer rates reported from prospective observational studies in patients treated with tumour necrosis factor inhibitors
  1. Xavier Mariette1,
  2. Alan Vaughan Reynolds2,
  3. Paul Emery3
  1. 1Service de Rhumatologie, Université Paris-Sud, AP-HP, Le Kremlin Bicetre, France
  2. 2Reynolds Clinical Sciences Ltd, Eastleigh, Hampshire, UK
  3. 3Section of Musculoskeletal Disease, University of Leeds, Leeds, UK
  1. Correspondence to Professor Xavier Mariette, Service de Rhumatologie, Le Kremlin Bicetre 94275, France; xavier.mariette{at}bct.aphp.fr

https://doi.org/10.1136/annrheumdis-2012-202478

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    We recently published a meta-analysis of malignancy rates reported from prospective observational studies in patients treated with tumour necrosis factor inhibitors (TNF-I).1 While there was no increase in the rates of all-site malignancy or lymphoma, there was an increased risk of non-melanoma skin cancer (NMSC) (1.45, 95% CI 1.15 to 1.76).

    The skin cancer analysis included data from an abstract from the British Society for Rheumatology Biologics Register (BSRBR)2 that has since been published as a full paper with different …

    View Full Text

    Footnotes

    • Competing interests XM has received research grants or honoraria from Bristol Myers Squibb, GSK, Pfizer and Roche; AR was an employee of Wyeth Europa and had held shares in Wyeth and currently has Pfizer share options, and has undertaken consultancy work for UCB Pharma and Pfizer; PE has received research grants or honoraria from Bristol Myers Squibb, GSK, Pfizer and Roche. This work was undertaken without external funding.

    • Provenance and peer review Not commissioned; internally peer reviewed.

    • Xavier Mariette, Marco Matucci-Cerinic, Karel Pavelka, Peter Taylor, Ronald van Vollenhoven, Rebecca Heatley, Claire Walsh, Richard Lawson, Alan Vaughan Reynolds, Paul Emery